Because TRAIL induces apoptosis selectively in tumor cells, TRAIL-targeting agents are considered promising candidates for cancer prevention and treatment, but their clinical application is hindered by the TRAIL-resistance of many cancer cells. This evidence concerns the gene TNFSF10 and cancer.